Facebook Twitter YouTube  
Contact Us
Search Clinical Trials
Home > Clinical Trials & Research > Search Clinical Trials
Print

Clinical Trials & Research

Search Clinical Trials

Clinical Trials

New Search
Title   A Study in Second Line Metastatic Colorectal Cancer
Disease/Condition   Colorectal Cancer
Description   The purpose of this study is to compare overall survival in patients with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
Eligibility Criteria   To be eligible for this study, patients must meet several criteria, including but not limited to the following:

* Patients must be 18 Years and older

* Subjects must have histologically or cytologically confirmed metastatic colorectal cancer (patients are eligible to enroll irrespective of KRAS mutation status).

* The patient has received first-line combination therapy of bevacizumab, oxaliplatin, and a fluoropyrimidine for metastatic disease and:
* Experienced radiographic disease progression during first-line therapy, OR
* Experienced radiographic disease progression within 6 months after the last dose of first-line therapy, OR
* Discontinued part or all of first-line therapy due to toxicity and experienced radiographic disease progression within 6 months after the last dose of first-line therapy.

Principal Investigator   Sanjay Goel, MD
Phone   (718) 405-2488
Contact Email   sgoel@montefiore.org
Post Date   08/04/2010
Protocol Number   10-12-384/West
Status   Recruiting
Current Trial Type   Interventional
Montefiore Clinical Trial   No
CHAM Clinical Trial   No